Hyderabad:23/5/21: Bharat Biotech may commence paediatric trials of its Covid-19 vaccine Covaxin from June, a senior company official said.
The vaccine maker has already received permission to carry out trials on children aged 2-18 years.
Bharat Biotech’s Business Development & International Advocacy Head, Dr. Raches Ella, exuded confidence that vaccines for kids may get the license in the third quarter of this year.
Holding a virtual conversation with members of FICCI Ladies Organisation (FLO) Hyderabad on “All About Vaccines, he said that the company expected approval from the World Health Organisation (WHO) for Covaxin by the end of the third or fourth quarter.
Ella also said Bharat Biotech will be ramping up the manufacturing capacity of Covaxin to 700 million doses by the end of this year.
“We are happy to have the full support of the government because of which we are able to stand where we are today in this journey. The vaccine is co-developed by us and ICMR. The Government placed an advanced purchase order of Rs 1,500 crore. This will help us to increase our risk appetite. That is why we are expanding to Bangalore and Gujarat,” he said.
Also seeking to dispel various myths about vaccines, he said that they are safe and everyone should take vaccines.
Replying to a query by Consultant, Breast Oncology & Oncoplastic Surgeon, Dr. Pragnya Chigurupati, who moderated the talk, Ella said the success probability of a vaccine is just 6 percent from discovery to development.